Loyal Valley Capital is a thematic, research-driven private equity firm.
Business Model:
Revenue: $0
Employees: 0-0
Address: No.1257 Mingyue Road,
City: Pudong
State: shanghai municipality
Zip: 200120
Country: CN
Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from the secular industry transformations in China. With over US$1.6 billion of assets under management, LVC mainly focuses on the following segments: Consumer (TMT, Internet, and Education), Healthcare, and Advanced Manufacturing. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and utilize extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises. LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM, known for its industry leading research and award-winning investment records.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2017 | The Child Academy | Venture Round | - |
3/2018 | Children&s;s House Of Virtues | Venture Round | - |
11/2017 | Fortune Finance | Venture Round | - |
3/2018 | Kaishu Jianggushi | Series B | 24.7M |
3/2019 | Wajijia Entertainment | Series A | - |
8/2020 | Sinovent | Series C | 144.7M |
5/2020 | Beaver Education | Series D | - |
2/2018 | GeneCast Biotechnology | Series C | 33M |
8/2018 | Teligene | Series B | - |
6/2020 | JW Therapeutics | Series B | 0 |
8/2016 | Kangning Hospital | Private Equity Round | - |
11/2018 | Immupeutics Medicine | Venture Round | - |
9/2017 | Gaosi Education Group | Series C | 83.4M |
10/2018 | ByteDance | Equity | 3B |
2/2021 | Regor Therapeutics | Series B | 0 |
6/2017 | Studio9 | Series A | - |
11/2019 | Juvenile Get | Series A | 0 |
4/2019 | Juvenile Get | Seed Round | - |
11/2019 | Akeso Biopharma | Series D | 150M |
3/2021 | Xiaoxian Dun | Series C | - |
8/2017 | Linklogis | Series B | 30.1M |
11/2020 | CARsgen Therapeutics | Series C | 0 |
7/2018 | Shanghai Henlius Biotech | Venture Round | 0 |
5/2019 | Allist Pharmaceuticals | Series A | 173.9M |
11/2016 | China Mercy Health Group | Series A | - |
6/2020 | Heyuan Biotechnology | Series C | - |
7/2017 | Pipilu | Series B | - |
12/2017 | Sugarman Media | Series A | - |
3/2022 | Medilink Therapeutics | Series B | 70M |
5/2020 | Pop Mart | Private Equity Round | 100M |
4/2019 | InfiNovo | Series A | - |
10/2021 | Sciwind Biosciences | Series C | 0 |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
2/2023 | Zhishan Weixin Biotechnology | Series A | 296.6k |
3/2020 | Remegen | Private Equity Round | 0 |
12/2016 | Luogic Thinking | Series C | - |
8/2019 | Mahua Fun Age | Post-IPO Equity | - |
4/2020 | Mabwell Biotech | Series A | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
1/2017 | ECNUAS | Private Equity Round | - |
6/2022 | Frontera Therapeutics | Series B | 0 |
8/2022 | Jinyuansheng | Series B | 147.6M |
5/2017 | Haixue | Series C | - |
7/2022 | Ark Biosciences | Series D | - |
5/2018 | Sinovent | Series A | - |
2/2020 | Kaishu Jianggushi | Series C | 66M |
8/2016 | Linklogis | Series A | 15.1M |
2/2022 | Chen Xianggui | Series B | 15.8M |
3/2019 | Abbisko Therapeutics | Series B | 42M |
10/2020 | Zhaoke Ophthalmology Pharmaceutical | Series B | 0 |
5/2016 | Bilibili | Series C | 199.3M |
1/2017 | iDreamsky Technology | Private Equity Round | - |
8/2021 | Abogen Biosciences | Series C | 0 |
11/2016 | Shanghai Junshi Biosciences | Venture Round | - |
3/2020 | Abbisko Therapeutics | Series C | 70M |
2/2018 | JW Therapeutics | Venture Round | - |
1/2022 | Peijie Hotpot | Series A | 15.8M |
8/2017 | Rishiji | Venture Round | - |
6/2020 | HYGEIA Healthcare Group | Private Equity Round | - |
3/2018 | Didi | Private Equity Round | 0 |
3/2019 | Jinfuzi | Series C | - |
7/2020 | OBiO Technology | Series C | 28.5M |
9/2018 | WeShare | Series B | 0 |
4/2021 | EdiGene | Series B | 61.6M |
4/2018 | Innomed | Series B | - |
1/2019 | Innocare | Private Equity Round | 0 |
4/2019 | EVE Energy | Private Equity Round | - |
5/2019 | NetEase Cloud Music | Private Equity Round | - |
9/2016 | Sound Solutions | Private Equity Round | - |
11/2017 | Phyplus | Series A | - |
3/2021 | Medilink Therapeutics | Series A | 50M |
8/2018 | Chaodian Culture | Angel Round | - |
12/2016 | Xinshixiang | Series A | 2.7M |
10/2018 | Linklogis | Series C | 0 |
3/2021 | Arctic Vision | Series B | 0 |
10/2021 | Leads Biolabs | Series C | 0 |
11/2021 | Tripod Preclinical Research Laboratories | Venture Round | 0 |
6/2017 | Avary Holding | Private Equity Round | - |
5/2018 | Immune-Onc Therapeutics | Series B | - |
7/2022 | Ark Biosciences | Series D | - |
6/2022 | Frontera Therapeutics | Series B | 0 |
3/2022 | Medilink Therapeutics | Series B | 0 |
11/2021 | Tripod Preclinical Research Laboratories | Venture Round | 0 |
10/2021 | Sciwind Biosciences | Series C | 0 |
10/2021 | Leads Biolabs | Series C | 0 |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
8/2021 | Abogen Biosciences | Series C | 0 |
4/2021 | EdiGene | Series B | 0 |
3/2021 | Xiaoxian Dun | Series C | - |
Name | Price |
---|
Name | Size | Announced Date |
---|